Thrivent Financial for Lutherans Has $1.29 Million Position in STAAR Surgical (NASDAQ:STAA)

Thrivent Financial for Lutherans grew its stake in shares of STAAR Surgical (NASDAQ:STAA - Free Report) by 37.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 53,037 shares of the medical instruments supplier's stock after acquiring an additional 14,422 shares during the period. Thrivent Financial for Lutherans owned about 0.11% of STAAR Surgical worth $1,288,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Intech Investment Management LLC bought a new position in shares of STAAR Surgical during the third quarter worth about $463,000. FMR LLC lifted its holdings in STAAR Surgical by 79.3% during the 3rd quarter. FMR LLC now owns 7,092 shares of the medical instruments supplier's stock worth $263,000 after buying an additional 3,136 shares during the last quarter. Erste Asset Management GmbH acquired a new position in shares of STAAR Surgical in the 3rd quarter worth approximately $788,000. Holocene Advisors LP bought a new stake in shares of STAAR Surgical in the 3rd quarter valued at approximately $1,096,000. Finally, HighTower Advisors LLC bought a new stake in shares of STAAR Surgical in the 3rd quarter valued at approximately $336,000. 96.70% of the stock is owned by institutional investors and hedge funds.

STAAR Surgical Price Performance

NASDAQ:STAA traded down $1.48 during midday trading on Friday, reaching $15.92. The stock had a trading volume of 2,394,979 shares, compared to its average volume of 781,439. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $52.68. The stock has a market capitalization of $785.25 million, a P/E ratio of -38.83 and a beta of 0.75. The firm's fifty day simple moving average is $18.82 and its 200-day simple moving average is $24.71.

Remove Ads

Analysts Set New Price Targets

A number of research firms have commented on STAA. Needham & Company LLC reaffirmed a "hold" rating on shares of STAAR Surgical in a report on Thursday, February 27th. Mizuho lowered STAAR Surgical from an "outperform" rating to a "neutral" rating and reduced their price target for the stock from $45.00 to $17.00 in a research report on Wednesday, February 12th. Jefferies Financial Group cut STAAR Surgical from a "buy" rating to a "hold" rating in a research note on Wednesday, February 12th. William Blair lowered STAAR Surgical from an "outperform" rating to a "market perform" rating in a research report on Wednesday, February 12th. Finally, Canaccord Genuity Group lowered their target price on STAAR Surgical from $28.00 to $17.00 and set a "hold" rating on the stock in a research note on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $25.29.

Insider Buying and Selling at STAAR Surgical

In other news, major shareholder Broadwood Partners, L.P. purchased 8,221 shares of the business's stock in a transaction on Thursday, January 16th. The stock was purchased at an average price of $21.50 per share, with a total value of $176,751.50. Following the acquisition, the insider now directly owns 10,878,007 shares in the company, valued at approximately $233,877,150.50. The trade was a 0.08 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders purchased a total of 1,128,072 shares of company stock valued at $18,842,293 in the last ninety days. Company insiders own 1.00% of the company's stock.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.